Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Persistence and other treatment patterns among bio-experienced patients with Crohn's disease initiated on ustekinumab or adalimumab.
Zhdanava M, Zhao R, Manceur AM, Ding Z, Kachroo S, Holiday C, Lefebvre P, Pilon D. Zhdanava M, et al. Among authors: kachroo s. J Manag Care Spec Pharm. 2023 Aug;29(8):907-916. doi: 10.18553/jmcp.2023.29.8.907. J Manag Care Spec Pharm. 2023. PMID: 37523319 Free PMC article.
BACKGROUND: Real-world data on persistence on ustekinumab and adalimumab among bio-experienced patients with Crohn's disease (CD) are limited. OBJECTIVE: To compare treatment persistence and describe switching, restart, and dose titration among bio-experienced patients wit …
BACKGROUND: Real-world data on persistence on ustekinumab and adalimumab among bio-experienced patients with Crohn's disease (CD) are …
Economic and clinical burden of chronic corticosteroid use in patients with Crohn[apos]s disease initiated on biologic or conventional therapies in the US: A retrospective claims study.
Zhdanava M, Zhao R, Manceur AM, Ding Z, Boudreau J, Kachroo S, Kerner C, Izanec J, Pilon D. Zhdanava M, et al. Among authors: kachroo s. J Am Pharm Assoc (2003). 2024 Mar-Apr;64(2):386-394.e10. doi: 10.1016/j.japh.2023.11.014. Epub 2023 Nov 11. J Am Pharm Assoc (2003). 2024. PMID: 37956768
The economic impact of suboptimal treatment and treatment switch among patients with Crohn's disease treated with a first-line biologic - A US retrospective claims database study.
Gagnon-Sanschagrin P, Sanon M, Davidson M, Willey C, Kachroo S, Hoops T, Naessens D, Guerin A, Cloutier M. Gagnon-Sanschagrin P, et al. Among authors: kachroo s. J Med Econ. 2024 Jan-Dec;27(1):931-940. doi: 10.1080/13696998.2024.2374645. Epub 2024 Jul 16. J Med Econ. 2024. PMID: 38965985 Free article.
Comparison of real-world healthcare resource utilization among advanced therapy-naïve and advanced therapy-experienced patients with ulcerative colitis initiated on ustekinumab or vedolizumab.
Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Korsiak J, Lefebvre P, Kerner C, Pilon D. Zhdanava M, et al. Among authors: kachroo s. Curr Med Res Opin. 2024 Sep;40(9):1555-1562. doi: 10.1080/03007995.2024.2388839. Epub 2024 Aug 13. Curr Med Res Opin. 2024. PMID: 39104290
90 results